| Document Date: 2013-09-04 01:15:50
Open Document File Size: 177,52 KBShare Result on Facebook
City Niederman / Stockholm / / Company Moberley SA / Australian Technical Advisory Group / / Continent Australia / / Country Japan / United Kingdom / Sweden / Wales / / Event Product Recall / Product Issues / / MedicalCondition presumptive pneumococcal pneumonia / pneumonia / HIV / lymphoma / multiple myeloma / disease / cellulitis/abscess / pneumococcal disease / invasive pneumococcal disease / chronic / pneumococcal bacteraemia/ septicaemia / pneumococcal meningitis / diabetes / clinical disease / pulmonary disease / nephrotic syndrome / chronic disease / AIDS / Infectious Diseases / pneumococcal infection / chronic medical conditions / illness / MS / influenza / / MedicalTreatment vaccination / / Organization National Science Foundation / Therapeutic Goods Administration / Pneumococcal Working Party / Medicare / / Person Aboriginal Strait Islander / Torres Strait Islander (Indigenous) / Torres Strait Islander / / Position Governor / VP / et al / / Product batch / / ProvinceOrState Alaska / Mississippi / / Technology transplantation / pdf / / URL http /
SocialTag |
Australian Technical Advisory Group on Immunisation (ATAGI) statement regarding updated recommendations for revaccination of23-valent pneumococcal polysaccharide vaccine (23vPPV), PNEUMOVAX-23® in adults